NASDAQ:ALT

Altimmune Competitors

$12.67
+0.10 (+0.80 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.45
Now: $12.67
$13.02
50-Day Range
$12.57
MA: $15.02
$19.58
52-Week Range
$2.88
Now: $12.67
$35.10
Volume768,416 shs
Average Volume1.60 million shs
Market Capitalization$470.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51

Competitors

Altimmune (NASDAQ:ALT) Vs. ZNTL, NGM, MORF, MDGL, KURA, and FGEN

Should you be buying ALT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Altimmune, including Zentalis Pharmaceuticals (ZNTL), NGM Biopharmaceuticals (NGM), Morphic (MORF), Madrigal Pharmaceuticals (MDGL), Kura Oncology (KURA), and FibroGen (FGEN).

Altimmune (NASDAQ:ALT) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Valuation & Earnings

This table compares Altimmune and Zentalis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Altimmune$5.80 million81.15$-20,520,000.00($0.98)-12.93
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A

Zentalis Pharmaceuticals has lower revenue, but higher earnings than Altimmune.

Analyst Ratings

This is a breakdown of recent recommendations for Altimmune and Zentalis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Altimmune00603.00
Zentalis Pharmaceuticals00703.00

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. Zentalis Pharmaceuticals has a consensus price target of $56.4286, suggesting a potential upside of 23.58%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than Zentalis Pharmaceuticals.

Insider & Institutional Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. 2.7% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Altimmune and Zentalis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Altimmune-659.33%-46.39%-38.32%
Zentalis PharmaceuticalsN/AN/AN/A

Summary

Zentalis Pharmaceuticals beats Altimmune on 5 of the 8 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Risk & Volatility

Altimmune has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.

Valuation & Earnings

This table compares Altimmune and NGM Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Altimmune$5.80 million81.15$-20,520,000.00($0.98)-12.93
NGM Biopharmaceuticals$103.54 million18.10$-42,790,000.00($0.85)-28.74

Altimmune has higher earnings, but lower revenue than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Altimmune and NGM Biopharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Altimmune00603.00
NGM Biopharmaceuticals00523.29

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. NGM Biopharmaceuticals has a consensus price target of $39.1111, suggesting a potential upside of 60.09%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than NGM Biopharmaceuticals.

Insider & Institutional Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 2.7% of Altimmune shares are owned by insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Altimmune and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Altimmune-659.33%-46.39%-38.32%
NGM Biopharmaceuticals-91.64%-29.47%-25.58%

Summary

NGM Biopharmaceuticals beats Altimmune on 9 of the 15 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Risk & Volatility

Altimmune has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Profitability

This table compares Altimmune and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Altimmune-659.33%-46.39%-38.32%
MorphicN/A-36.62%-20.69%

Valuation & Earnings

This table compares Altimmune and Morphic's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Altimmune$5.80 million81.15$-20,520,000.00($0.98)-12.93
Morphic$16.98 million110.19$-43,330,000.00($2.69)-21.43

Altimmune has higher earnings, but lower revenue than Morphic. Morphic is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Altimmune and Morphic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Altimmune00603.00
Morphic00203.00

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. Morphic has a consensus price target of $63.3333, suggesting a potential upside of 9.84%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than Morphic.

Insider & Institutional Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 2.7% of Altimmune shares are owned by insiders. Comparatively, 39.5% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Altimmune beats Morphic on 7 of the 13 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Volatility & Risk

Altimmune has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Profitability

This table compares Altimmune and Madrigal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Altimmune-659.33%-46.39%-38.32%
Madrigal PharmaceuticalsN/A-47.64%-43.21%

Valuation and Earnings

This table compares Altimmune and Madrigal Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Altimmune$5.80 million81.15$-20,520,000.00($0.98)-12.93
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-21.21

Altimmune has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Altimmune and Madrigal Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Altimmune00603.00
Madrigal Pharmaceuticals03702.70

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. Madrigal Pharmaceuticals has a consensus price target of $167.60, suggesting a potential upside of 45.02%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Madrigal Pharmaceuticals.

Institutional & Insider Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 74.2% of Madrigal Pharmaceuticals shares are owned by institutional investors. 2.7% of Altimmune shares are owned by company insiders. Comparatively, 41.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Altimmune beats Madrigal Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Volatility & Risk

Altimmune has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Profitability

This table compares Altimmune and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Altimmune-659.33%-46.39%-38.32%
Kura OncologyN/A-30.96%-28.02%

Valuation and Earnings

This table compares Altimmune and Kura Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Altimmune$5.80 million81.15$-20,520,000.00($0.98)-12.93
Kura OncologyN/AN/A$-63,140,000.00($1.51)-18.23

Altimmune has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Altimmune and Kura Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Altimmune00603.00
Kura Oncology011002.91

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 43.70%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Kura Oncology.

Institutional & Insider Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 94.7% of Kura Oncology shares are owned by institutional investors. 2.7% of Altimmune shares are owned by company insiders. Comparatively, 11.0% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Kura Oncology beats Altimmune on 7 of the 13 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Altimmune and FibroGen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Altimmune00603.00
FibroGen15202.13

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. FibroGen has a consensus price target of $45.8333, suggesting a potential upside of 132.30%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than FibroGen.

Profitability

This table compares Altimmune and FibroGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Altimmune-659.33%-46.39%-38.32%
FibroGen-191.78%-48.19%-27.72%

Institutional & Insider Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 75.1% of FibroGen shares are owned by institutional investors. 2.7% of Altimmune shares are owned by company insiders. Comparatively, 3.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Altimmune and FibroGen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Altimmune$5.80 million81.15$-20,520,000.00($0.98)-12.93
FibroGen$256.58 million7.04$-76,970,000.00($0.89)-22.17

Altimmune has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Altimmune has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.


Altimmune Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$45.66+11.5%$1.87 billionN/A0.00Analyst Report
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.43+0.4%$1.87 billion$103.54 million-18.37Insider Selling
MORF
Morphic
1.1$57.66+0.1%$1.87 billion$16.98 million-36.96Insider Selling
Decrease in Short Interest
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$115.57+1.3%$1.85 billionN/A-10.44
Kura Oncology logo
KURA
Kura Oncology
1.6$27.52+4.0%$1.82 billionN/A-16.88
FibroGen logo
FGEN
FibroGen
1.8$19.73+0.8%$1.81 billion$256.58 million-7.56Analyst Report
News Coverage
Gap Up
MacroGenics logo
MGNX
MacroGenics
1.4$29.57+1.7%$1.77 billion$64.19 million-9.45Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94+0.1%$1.77 billion$14.87 million-14.16Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.76+0.2%$1.73 billion$1.63 billion14.05Decrease in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$23.91+0.3%$1.71 billion$26.87 million-12.52Insider Selling
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.31+1.5%$1.66 billion$428.41 million14.94News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.5$31.29+10.6%$1.66 billion$392.76 million12.98Analyst Upgrade
High Trading Volume
News Coverage
Gap Down
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.79+1.2%$1.63 billion$320,000.00-8.70Analyst Report
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.46+0.9%$1.62 billionN/A0.00High Trading Volume
Analyst Revision
uniQure logo
QURE
uniQure
1.7$34.88+5.0%$1.57 billion$7.28 million-9.25
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.73+0.1%$1.57 billion$2.34 million-9.63
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.07+0.6%$1.55 billionN/A-6.07High Trading Volume
Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.66+2.2%$1.52 billion$145.97 million-6.74
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$25.03+2.0%$1.51 billion$175.34 million-14.72Analyst Report
Analyst Revision
News Coverage
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.47+0.7%$1.51 billionN/A0.00
Keros Therapeutics logo
KROS
Keros Therapeutics
1.4$64.05+8.4%$1.49 billionN/A0.00Increase in Short Interest
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.72+5.0%$1.47 billionN/A0.00Insider Selling
Increase in Short Interest
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.27+1.2%$1.45 billion$82.27 million-17.73
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$36.03+0.2%$1.44 billionN/A-150.13
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.67+3.6%$1.43 billionN/A0.00
Generation Bio logo
GBIO
Generation Bio
1.8$25.39+2.6%$1.43 billionN/A0.00Increase in Short Interest
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.79+2.1%$1.42 billion$6.20 million-14.38
ATBPD
Antibe Therapeutics
0.1$3.66+6.0%$1.42 billion$7.51 million-6.10
Endo International logo
ENDP
Endo International
1.5$6.11+1.0%$1.41 billion$2.91 billion-8.99
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.81+2.6%$1.39 billionN/A-3.01
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$27.49+3.2%$1.37 billion$19.89 million-12.97
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.46+3.8%$1.37 billion$4.23 million-19.60Increase in Short Interest
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.58+0.1%$1.34 billion$73.41 million-4.35Unusual Options Activity
Shattuck Labs logo
STTK
Shattuck Labs
1.4$32.11+4.2%$1.34 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$36.37+5.0%$1.33 billionN/A0.00Analyst Upgrade
OLMA
Olema Pharmaceuticals
1.6$32.48+2.3%$1.30 billionN/A0.00Increase in Short Interest
Zymeworks logo
ZYME
Zymeworks
1.8$27.92+1.9%$1.29 billion$29.54 million-7.41News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.7$22.89+11.0%$1.28 billionN/A0.00Insider Selling
Unusual Options Activity
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.97+2.5%$1.22 billionN/A-2.79
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$33.06+0.1%$1.21 billionN/A-18.37
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89+2.0%$1.21 billion$4.23 million-8.88News Coverage
Gap Up
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$32.44+0.1%$1.20 billionN/A0.00
Innoviva logo
INVA
Innoviva
1.4$11.63+0.3%$1.18 billion$261.02 million5.93
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$30.37+1.4%$1.17 billionN/A0.00Increase in Short Interest
Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.24+1.6%$1.17 billion$59.70 million-192.40
NKTX
Nkarta
1.8$35.54+4.3%$1.17 billionN/A0.00High Trading Volume
Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$9.96+1.1%$1.13 billion$35.22 million-7.27
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$25.57+2.5%$1.12 billion$230,000.00-11.89
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.16+1.9%$1.12 billion$42.12 million-11.97
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.